부산대학교 도서관

Introduction: Using data from the ertugliflozin cardiovascular outcomes trial in patients with type 2 diabetes mellitus (VERTIS CV; NCT01986881), associations between the initial estimated glomerular filtration rate (eGFR) "dip" with eGFR slope, glucosuria/natriuresis-related measures, and safety were investigated. Methods: Patients were categorized into tertiles based on change in eGFR at week 6: >+1.00 mL/min/1.73 m[sup.2] (tertile 1), >5.99 and [Less-Than or Equal To]+1.00 (tertile 2), and [Less-Than or Equal To]6.00 (tertile 3). eGFR slope after week 6 and week 18 was assessed by tertile. Glucosuria/natriuresis-related measures were also determined. Adverse events (AEs) were analyzed in the acute (baseline-week 6) and chronic periods (week 6-30 days after last dose of trial medication). Results: In the ertugliflozin group, chronic eGFR slopes (95% CI, mL/min/1.73 m[sup.2]/year; weeks 6-156) were 0.76 (1.03, 0.50), 0.29 (0.51, 0.07), and 0.05 (0.26, 0.17) in tertiles 1, 2, and 3, respectively (p value Keywords: Kidney protection, Kidney function decline, Glomerular filtration rate, Diabetic nephropathy, Type 2 diabetes mellitus, Clinical trial, Sodium-glucose cotransporter 2 inhibitor
Author(s): David Z.I. Cherney [a]; Francesco Cosentino [b]; Samuel Dagogo-Jack [c]; Darren K. McGuire [d]; Richard E. Pratley [e]; Robert Frederich [f]; Mario Maldonado [g]; Chih-Chin Liu [h]; Annpey Pong [...]